BCBS Arizona

Does BCBS Arizona cover Wegovy?

Quick answer · Weight Loss

BCBS Arizona does not cover it for weight loss on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Not covered. This PCG explicitly states it covers non-weight loss indications only. For use in weight loss, the member is directed to their benefit plan book. Weight loss coverage is outside the scope of this document.
  • ACA Marketplace: Not covered. This PCG explicitly states it covers non-weight loss indications only. For use in weight loss, the member is directed to their benefit plan book. Weight loss coverage is outside the scope of this document.

Last verified June 2, 2026. Policy effective May 16, 2024. Source: Download. How we verify this data →

Check your card for your exact plan →

Wegovy for Weight Loss

What BCBS Arizona requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Not covered

This PCG explicitly states it covers non-weight loss indications only. For use in weight loss, the member is directed to their benefit plan book. Weight loss coverage is outside the scope of this document.

Policy note: This PCG explicitly excludes weight loss as an indication. Members seeking Wegovy for weight loss are directed to their benefit plan book. No PA criteria are established in this document for weight loss.

Policy effective May 16, 2024 · verified June 2, 2026 · source: Download

ACA Marketplace

Not covered

This PCG explicitly states it covers non-weight loss indications only. For use in weight loss, the member is directed to their benefit plan book. Weight loss coverage is outside the scope of this document.

Policy note: This PCG explicitly excludes weight loss as an indication. Members seeking Wegovy for weight loss are directed to their benefit plan book. No PA criteria are established in this document for weight loss.

Policy effective May 16, 2024 · verified June 2, 2026 · source: Download

Wegovy for Heart Disease Risk Reduction

What BCBS Arizona requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 45 and older
  • BMI of 27 or higher
  • A1C no higher than 6.5%
  • 6 months of a documented diet and exercise program
  • Prescribed by or in consultation with a specialist
  • Established cardiovascular disease (MI, stroke, and PAD)
  • On guideline-directed medical therapy (statin, platelet_aggregation_inhibitor, ACE_inhibitor, ARB, beta_blocker, calcium_channel_blocker, and ARNI)
  • Lab results confirming eligibility from the last 12 months
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Initial Approval: Wegovy for CV Risk Reduction

All of:

  • Age >= 45 years
  • BMI >= 27 kg/m2
  • Established cardiovascular disease (prior MI, prior ischemic or hemorrhagic stroke, or symptomatic PAD as defined below)
  • HbA1c < 6.5% within past 12 months
  • Does NOT have type 1 or type 2 diabetes (gestational diabetes excluded from this restriction)
  • Does NOT have NYHA Class IV heart failure
  • Where clinically appropriate, is on guideline-directed standard of care for CV condition (e.g., lipid-lowering therapy, platelet aggregation inhibitors, ACE inhibitors or ARBs, beta blockers, calcium channel blockers, ARNI)
  • Will be used as adjunct to a program supporting reduced calorie diet (>= 500 kcal/day reduction) and >= 150 min/week activity
  • Prescribed by or in consultation with a Cardiologist
  • Failure, contraindication, or intolerance to THREE generic equivalents (if available) for at least 3 months each
  • No personal or family history of medullary thyroid carcinoma or MEN2
  • No prior serious hypersensitivity reaction to semaglutide
  • No concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists
  • No chronic pancreatitis or recent (within 180 days) acute pancreatitis
  • No severe gastroparesis
  • Not pregnant (if of childbearing potential)

Plus any one of:

  • Prior myocardial infarction
  • Prior ischemic or hemorrhagic stroke
  • Symptomatic PAD: intermittent claudication with ABI < 0.85 at rest
  • Symptomatic PAD: peripheral arterial revascularization procedure
  • Symptomatic PAD: amputation due to atherosclerotic disease

Continuation/Renewal: Wegovy for CV Risk Reduction

All of:

  • Continues to be seen by physician specializing in diagnosis or in consultation with a Cardiologist
  • Confirmed established cardiovascular disease (same qualifying events as initial)
  • HbA1c < 6.5% within past 12 months
  • Does NOT have type 1 or type 2 diabetes
  • Does NOT have NYHA Class IV heart failure
  • Adherence to medication and guideline-directed standard of care for established CV condition
  • Requested dose is at least 1.7 mg weekly
  • Will be used as adjunct to reduced calorie diet (>= 500 kcal/day) and >= 150 min/week activity
  • Failure, contraindication, or intolerance to THREE generic equivalents for at least 3 months each
  • No personal or family history of medullary thyroid carcinoma or MEN2
  • No prior serious hypersensitivity reaction to semaglutide
  • No concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists
  • No chronic pancreatitis or recent (within 180 days) acute pancreatitis
  • No severe gastroparesis
  • No sustained increase in resting heart rate
  • Not pregnant (if of childbearing potential)

Plus any one of:

  • Reduction of >= 5% in body weight from baseline
  • Reduction of >= 3% body weight from baseline WITH decrease in LDL or triglycerides
  • Reduction of >= 3% body weight from baseline WITH decrease in waist circumference
  • Reduction of >= 3% body weight from baseline WITH decrease in blood pressure

Documentation to bring

  • Completed prior authorization request form
  • Chart notes documenting established cardiovascular disease (prior MI, prior stroke, or symptomatic PAD with qualifying criteria)
  • HbA1c lab result within past 12 months (must be < 6.5%)
  • Documentation of current body weight / BMI (>= 27 kg/m2)
  • Documentation of current guideline-directed standard of care medications for CV condition, or clinical reason GDMT is not appropriate
  • Documentation of failure, contraindication, or intolerance to three generic equivalents for at least 3 months each
  • Prescriber attestation that patient does not have type 1 or type 2 diabetes
  • Prescriber attestation that patient does not have NYHA Class IV heart failure
  • For renewal: chart notes documenting >= 5% body weight reduction OR >= 3% reduction with qualifying secondary benefit
  • For renewal: lab values confirming safe continued use
  • For renewal: supporting clinical documentation of adherence

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, At renewal, patient must have achieved and maintained ONE of: (1) >= 5% reduction in body weight from baseline, OR (2) >= 3% body weight reduction from baseline WITH at least one of: decrease in LDL or triglycerides, decrease in waist circumference, or decrease in blood pressure. Also requires continued adherence to medication and guideline-directed standard of care for established CV condition. Minimum dose of 1.7 mg weekly required at renewal. HbA1c < 6.5% and absence of T1DM/T2DM are re-verified at continuation. GDMT requirement is re-verified at continuation (adherence required). Note: brand-specific criteria (3 generic equivalent failures) are also re-checked at renewal, and staying on a maintenance dose of at least 1.7 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Type 2 diabetes (gestational diabetes is excluded from this restriction)
  • NYHA Class IV heart failure
  • Personal or family history of medullary thyroid carcinoma or MEN2
  • Prior serious hypersensitivity reaction to semaglutide
  • Concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists (e.g., Ozempic, Rybelsus, Trulicity, tirzepatide)
  • Chronic pancreatitis or recent (within 180 days) acute pancreatitis
  • Severe gastroparesis
  • Sustained increase in resting heart rate (continuation only)
  • Pregnancy
  • Type 1 diabetes

Policy note: This PCG applies to Commercial and/or Marketplace plans. It does NOT apply to Federal Employee Program, Medicare Advantage, Medicaid, or out-of-state BCBS plans. Brand-specific criteria require failure, contraindication, or intolerance to THREE generic equivalents (if available) for at least 3 months each. Qualifying PAD includes: (1) intermittent claudication with ABI < 0.85 at rest, (2) peripheral arterial revascularization procedure, or (3) amputation due to atherosclerotic disease. GDMT examples listed include lipid-lowering therapy, platelet aggregation inhibitors, ACE inhibitors or ARBs, beta blockers, calcium channel blockers, and angiotensin receptor neprilysin inhibitor (ARNI). Manufacturer samples/assistance not accepted for continuation of therapy. Initial approval is 6 months or end of plan year; continuation is 12 months or end of plan year. HbA1c lookback period is 12 months.

Policy effective May 16, 2024 · verified June 2, 2026 · source: Download

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 45 and older
  • BMI of 27 or higher
  • A1C no higher than 6.5%
  • 6 months of a documented diet and exercise program
  • Prescribed by or in consultation with a specialist
  • Established cardiovascular disease (MI, stroke, and PAD)
  • On guideline-directed medical therapy (statin, platelet_aggregation_inhibitor, ACE_inhibitor, ARB, beta_blocker, calcium_channel_blocker, and ARNI)
  • Lab results confirming eligibility from the last 12 months
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Initial Approval: Wegovy for CV Risk Reduction

All of:

  • Age >= 45 years
  • BMI >= 27 kg/m2
  • Established cardiovascular disease (prior MI, prior ischemic or hemorrhagic stroke, or symptomatic PAD as defined below)
  • HbA1c < 6.5% within past 12 months
  • Does NOT have type 1 or type 2 diabetes (gestational diabetes excluded from this restriction)
  • Does NOT have NYHA Class IV heart failure
  • Where clinically appropriate, is on guideline-directed standard of care for CV condition (e.g., lipid-lowering therapy, platelet aggregation inhibitors, ACE inhibitors or ARBs, beta blockers, calcium channel blockers, ARNI)
  • Will be used as adjunct to a program supporting reduced calorie diet (>= 500 kcal/day reduction) and >= 150 min/week activity
  • Prescribed by or in consultation with a Cardiologist
  • Failure, contraindication, or intolerance to THREE generic equivalents (if available) for at least 3 months each
  • No personal or family history of medullary thyroid carcinoma or MEN2
  • No prior serious hypersensitivity reaction to semaglutide
  • No concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists
  • No chronic pancreatitis or recent (within 180 days) acute pancreatitis
  • No severe gastroparesis
  • Not pregnant (if of childbearing potential)

Plus any one of:

  • Prior myocardial infarction
  • Prior ischemic or hemorrhagic stroke
  • Symptomatic PAD: intermittent claudication with ABI < 0.85 at rest
  • Symptomatic PAD: peripheral arterial revascularization procedure
  • Symptomatic PAD: amputation due to atherosclerotic disease

Continuation/Renewal: Wegovy for CV Risk Reduction

All of:

  • Continues to be seen by physician specializing in diagnosis or in consultation with a Cardiologist
  • Confirmed established cardiovascular disease (same qualifying events as initial)
  • HbA1c < 6.5% within past 12 months
  • Does NOT have type 1 or type 2 diabetes
  • Does NOT have NYHA Class IV heart failure
  • Adherence to medication and guideline-directed standard of care for established CV condition
  • Requested dose is at least 1.7 mg weekly
  • Will be used as adjunct to reduced calorie diet (>= 500 kcal/day) and >= 150 min/week activity
  • Failure, contraindication, or intolerance to THREE generic equivalents for at least 3 months each
  • No personal or family history of medullary thyroid carcinoma or MEN2
  • No prior serious hypersensitivity reaction to semaglutide
  • No concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists
  • No chronic pancreatitis or recent (within 180 days) acute pancreatitis
  • No severe gastroparesis
  • No sustained increase in resting heart rate
  • Not pregnant (if of childbearing potential)

Plus any one of:

  • Reduction of >= 5% in body weight from baseline
  • Reduction of >= 3% body weight from baseline WITH decrease in LDL or triglycerides
  • Reduction of >= 3% body weight from baseline WITH decrease in waist circumference
  • Reduction of >= 3% body weight from baseline WITH decrease in blood pressure

Documentation to bring

  • Completed prior authorization request form
  • Chart notes documenting established cardiovascular disease (prior MI, prior stroke, or symptomatic PAD with qualifying criteria)
  • HbA1c lab result within past 12 months (must be < 6.5%)
  • Documentation of current body weight / BMI (>= 27 kg/m2)
  • Documentation of current guideline-directed standard of care medications for CV condition, or clinical reason GDMT is not appropriate
  • Documentation of failure, contraindication, or intolerance to three generic equivalents for at least 3 months each
  • Prescriber attestation that patient does not have type 1 or type 2 diabetes
  • Prescriber attestation that patient does not have NYHA Class IV heart failure
  • For renewal: chart notes documenting >= 5% body weight reduction OR >= 3% reduction with qualifying secondary benefit
  • For renewal: lab values confirming safe continued use
  • For renewal: supporting clinical documentation of adherence

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, At renewal, patient must have achieved and maintained ONE of: (1) >= 5% reduction in body weight from baseline, OR (2) >= 3% body weight reduction from baseline WITH at least one of: decrease in LDL or triglycerides, decrease in waist circumference, or decrease in blood pressure. Also requires continued adherence to medication and guideline-directed standard of care for established CV condition. Minimum dose of 1.7 mg weekly required at renewal. HbA1c < 6.5% and absence of T1DM/T2DM are re-verified at continuation. GDMT requirement is re-verified at continuation (adherence required). Note: brand-specific criteria (3 generic equivalent failures) are also re-checked at renewal, and staying on a maintenance dose of at least 1.7 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Type 2 diabetes (gestational diabetes is excluded from this restriction)
  • NYHA Class IV heart failure
  • Personal or family history of medullary thyroid carcinoma or MEN2
  • Prior serious hypersensitivity reaction to semaglutide
  • Concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists (e.g., Ozempic, Rybelsus, Trulicity, tirzepatide)
  • Chronic pancreatitis or recent (within 180 days) acute pancreatitis
  • Severe gastroparesis
  • Sustained increase in resting heart rate (continuation only)
  • Pregnancy
  • Type 1 diabetes

Policy note: This PCG applies to Commercial and/or Marketplace plans. It does NOT apply to Federal Employee Program, Medicare Advantage, Medicaid, or out-of-state BCBS plans. Brand-specific criteria require failure, contraindication, or intolerance to THREE generic equivalents (if available) for at least 3 months each. Qualifying PAD includes: (1) intermittent claudication with ABI < 0.85 at rest, (2) peripheral arterial revascularization procedure, or (3) amputation due to atherosclerotic disease. GDMT examples listed include lipid-lowering therapy, platelet aggregation inhibitors, ACE inhibitors or ARBs, beta blockers, calcium channel blockers, and angiotensin receptor neprilysin inhibitor (ARNI). Manufacturer samples/assistance not accepted for continuation of therapy. Initial approval is 6 months or end of plan year; continuation is 12 months or end of plan year. HbA1c lookback period is 12 months.

Policy effective May 16, 2024 · verified June 2, 2026 · source: Download

Wegovy for Liver Disease (MASH)

What BCBS Arizona requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • 6 months of a documented diet and exercise program
  • Prescribed by or in consultation with a specialist
  • Confirmed MASH diagnosis by liver_biopsy, FibroScan_VCTE, ELF_test, and FIB-4, fibrosis stage F2 to F3
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Initial Approval: Wegovy for MASH

All of:

  • Age >= 18 years
  • Diagnosis of noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3)
  • At least THREE of the five metabolic risk factors (large waist circumference or BMI >= 30; TG >= 150 mg/dL or on specific treatment; low HDL or on specific treatment; BP >= 140/90 mmHg on two occasions or on treatment; diagnosis of T2DM)
  • Evidence of liver steatosis (> 5% by imaging or histology) with at least one cardiometabolic risk factor
  • Evidence of liver inflammation and hepatocellular injury (lobar inflammation and ballooning injury to hepatocytes)
  • No other causes of steatotic liver disease
  • Alcohol consumption < 20 g daily for females and < 30 g daily for males
  • Does NOT have Stage 4 fibrosis (cirrhosis)
  • Will be used as adjunct to program supporting reduced calorie diet (>= 500 kcal/day) and >= 150 min/week activity aiming for 7-10% weight loss
  • Prescribed by or in consultation with a Gastroenterologist or Hepatologist
  • Failure, contraindication, or intolerance to THREE generic equivalents (if available) for at least 3 months each
  • No personal or family history of medullary thyroid carcinoma or MEN2
  • No prior serious hypersensitivity reaction to semaglutide
  • No concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists
  • No chronic pancreatitis or recent (within 180 days) acute pancreatitis
  • No severe gastroparesis
  • Not pregnant (if of childbearing potential)

Plus any one of:

  • Liver biopsy within 2 years showing Stage 2 or 3 fibrosis with NASH/MASH (no significant weight change > 5% or use of medication that might affect NAS or fibrosis stage)
  • FibroScan with transient elastography within 3 months: >= 8.5 kPa AND controlled attenuation parameter >= 280 dB/m
  • Biochemical fibrosis test: PRO-C3 > 14 ng/mL OR ELF score >= 9
  • Combination of imaging (VCTE, ELF) and serologic tests (FIB-4 index)

Continuation/Renewal: Wegovy for MASH

All of:

  • Confirmed diagnosis of noncirrhotic MASH
  • Adherence to medication and lifestyle changes aiming for 7-10% weight loss
  • Continues to be seen by physician specializing in diagnosis or in consultation with a Gastroenterologist or Hepatologist
  • Failure, contraindication, or intolerance to THREE generic equivalents for at least 3 months each
  • No personal or family history of medullary thyroid carcinoma or MEN2
  • No concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists
  • No acute or chronic pancreatitis
  • No severe gastroparesis
  • No sustained increase in resting heart rate

Plus any one of:

  • Resolution of steatohepatitis with >= 2-point NAS reduction without worsening fibrosis (absence of ballooning [score=0] AND absence or mild lobular inflammation [score=0-1] AND no fibrosis progression >= 1 stage)
  • At least one stage improvement in fibrosis without worsening NAS
  • Stabilization of fibrosis by blood tests (LFTs) and non-invasive assessments

Documentation to bring

  • Completed prior authorization request form
  • Chart notes documenting diagnosis of noncirrhotic MASH with F2-F3 fibrosis
  • Documentation of at least THREE qualifying metabolic risk factors
  • ONE of the following fibrosis confirmation documents: liver biopsy report within 2 years showing Stage 2-3 fibrosis with MASH; OR FibroScan/VCTE result within 3 months (>= 8.5 kPa and CAP >= 280 dB/m); OR biochemical fibrosis test results (PRO-C3 > 14 ng/mL or ELF >= 9); OR combination of imaging and serologic tests (VCTE/ELF + FIB-4)
  • Lab results including lipids and liver function tests (LFTs)
  • Imaging or biopsy reports documenting liver steatosis > 5%
  • Documentation of liver inflammation and hepatocellular injury (ballooning on biopsy/pathology)
  • Documentation of current body weight
  • Alcohol consumption history confirming < 20 g/day (females) or < 30 g/day (males)
  • Documentation confirming absence of Stage 4 fibrosis (cirrhosis)
  • Documentation of failure, contraindication, or intolerance to three generic equivalents for at least 3 months each
  • For renewal: LFTs and non-invasive fibrosis assessment (imaging, biochemical) documenting clinical response
  • For renewal: supporting clinical documentation of weight and adherence to lifestyle program
  • For renewal: lab values confirming safe continued use

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for At renewal, patient must show ONE of: (1) Resolution of steatohepatitis with >= 2-point reduction in NAS without worsening fibrosis (demonstrated by both absence of ballooning [score=0] AND absence or mild lobular inflammation [score=0-1], plus no progression >= 1 fibrosis stage); OR (2) At least one stage improvement in fibrosis without worsening NAS; OR (3) Stabilization of fibrosis by blood tests (LFTs) and non-invasive assessments. Adherence to medication and lifestyle changes aiming for 7-10% weight loss is also required. Brand-specific criteria (3 generic equivalent failures) re-checked at renewal. Initial MASH fibrosis staging criteria (F2-F3, metabolic risk factors, alcohol limits) are NOT re-verified at continuation — only clinical response is assessed.

Not covered when

  • Stage 4 fibrosis (cirrhosis) — noncirrhotic MASH only
  • Other causes of steatotic liver disease (drug-induced, monogenic, alcohol-induced, cryptogenic)
  • Alcohol consumption >= 20 g/day for females or >= 30 g/day for males
  • Personal or family history of medullary thyroid carcinoma or MEN2
  • Prior serious hypersensitivity reaction to semaglutide
  • Concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists
  • Chronic pancreatitis or recent (within 180 days) acute pancreatitis
  • Severe gastroparesis
  • Sustained increase in resting heart rate (continuation only)
  • Pregnancy

Policy note: This PCG applies to Commercial and/or Marketplace plans. It does NOT apply to Federal Employee Program, Medicare Advantage, Medicaid, or out-of-state BCBS plans. Metabolic risk factors (need 3 of 5): (1) large waist circumference (men > 94 cm / women > 80 cm) OR BMI >= 30 kg/m2; (2) TG >= 150 mg/dL or on specific treatment; (3) HDL < 40 mg/dL (males) or < 50 mg/dL (females) or on specific treatment; (4) BP >= 140/90 mmHg on two occasions or on treatment; (5) T2DM diagnosis. Liver biopsy lookback is 2 years (24 months), with no significant weight change > 5% and no medication that might affect NAS or fibrosis stage. FibroScan/VCTE lookback is 3 months. No explicit lookback period stated for biochemical tests (PRO-C3, ELF) or FIB-4 combination approach. The MASH indication is approved under FDA accelerated approval. Brand-specific criteria require failure, contraindication, or intolerance to THREE generic equivalents (if available) for at least 3 months each. Manufacturer samples/assistance not accepted for continuation of therapy. Initial approval is 6 months or end of plan year; continuation is 12 months or end of plan year. Diabetes (T2DM) is listed as a qualifying metabolic risk factor, so T2DM is NOT excluded for this indication.

Policy effective May 16, 2024 · verified June 2, 2026 · source: Download

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • 6 months of a documented diet and exercise program
  • Prescribed by or in consultation with a specialist
  • Confirmed MASH diagnosis by liver_biopsy, FibroScan_VCTE, ELF_test, and FIB-4, fibrosis stage F2 to F3
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Initial Approval: Wegovy for MASH

All of:

  • Age >= 18 years
  • Diagnosis of noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3)
  • At least THREE of the five metabolic risk factors (large waist circumference or BMI >= 30; TG >= 150 mg/dL or on specific treatment; low HDL or on specific treatment; BP >= 140/90 mmHg on two occasions or on treatment; diagnosis of T2DM)
  • Evidence of liver steatosis (> 5% by imaging or histology) with at least one cardiometabolic risk factor
  • Evidence of liver inflammation and hepatocellular injury (lobar inflammation and ballooning injury to hepatocytes)
  • No other causes of steatotic liver disease
  • Alcohol consumption < 20 g daily for females and < 30 g daily for males
  • Does NOT have Stage 4 fibrosis (cirrhosis)
  • Will be used as adjunct to program supporting reduced calorie diet (>= 500 kcal/day) and >= 150 min/week activity aiming for 7-10% weight loss
  • Prescribed by or in consultation with a Gastroenterologist or Hepatologist
  • Failure, contraindication, or intolerance to THREE generic equivalents (if available) for at least 3 months each
  • No personal or family history of medullary thyroid carcinoma or MEN2
  • No prior serious hypersensitivity reaction to semaglutide
  • No concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists
  • No chronic pancreatitis or recent (within 180 days) acute pancreatitis
  • No severe gastroparesis
  • Not pregnant (if of childbearing potential)

Plus any one of:

  • Liver biopsy within 2 years showing Stage 2 or 3 fibrosis with NASH/MASH (no significant weight change > 5% or use of medication that might affect NAS or fibrosis stage)
  • FibroScan with transient elastography within 3 months: >= 8.5 kPa AND controlled attenuation parameter >= 280 dB/m
  • Biochemical fibrosis test: PRO-C3 > 14 ng/mL OR ELF score >= 9
  • Combination of imaging (VCTE, ELF) and serologic tests (FIB-4 index)

Continuation/Renewal: Wegovy for MASH

All of:

  • Confirmed diagnosis of noncirrhotic MASH
  • Adherence to medication and lifestyle changes aiming for 7-10% weight loss
  • Continues to be seen by physician specializing in diagnosis or in consultation with a Gastroenterologist or Hepatologist
  • Failure, contraindication, or intolerance to THREE generic equivalents for at least 3 months each
  • No personal or family history of medullary thyroid carcinoma or MEN2
  • No concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists
  • No acute or chronic pancreatitis
  • No severe gastroparesis
  • No sustained increase in resting heart rate

Plus any one of:

  • Resolution of steatohepatitis with >= 2-point NAS reduction without worsening fibrosis (absence of ballooning [score=0] AND absence or mild lobular inflammation [score=0-1] AND no fibrosis progression >= 1 stage)
  • At least one stage improvement in fibrosis without worsening NAS
  • Stabilization of fibrosis by blood tests (LFTs) and non-invasive assessments

Documentation to bring

  • Completed prior authorization request form
  • Chart notes documenting diagnosis of noncirrhotic MASH with F2-F3 fibrosis
  • Documentation of at least THREE qualifying metabolic risk factors
  • ONE of the following fibrosis confirmation documents: liver biopsy report within 2 years showing Stage 2-3 fibrosis with MASH; OR FibroScan/VCTE result within 3 months (>= 8.5 kPa and CAP >= 280 dB/m); OR biochemical fibrosis test results (PRO-C3 > 14 ng/mL or ELF >= 9); OR combination of imaging and serologic tests (VCTE/ELF + FIB-4)
  • Lab results including lipids and liver function tests (LFTs)
  • Imaging or biopsy reports documenting liver steatosis > 5%
  • Documentation of liver inflammation and hepatocellular injury (ballooning on biopsy/pathology)
  • Documentation of current body weight
  • Alcohol consumption history confirming < 20 g/day (females) or < 30 g/day (males)
  • Documentation confirming absence of Stage 4 fibrosis (cirrhosis)
  • Documentation of failure, contraindication, or intolerance to three generic equivalents for at least 3 months each
  • For renewal: LFTs and non-invasive fibrosis assessment (imaging, biochemical) documenting clinical response
  • For renewal: supporting clinical documentation of weight and adherence to lifestyle program
  • For renewal: lab values confirming safe continued use

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for At renewal, patient must show ONE of: (1) Resolution of steatohepatitis with >= 2-point reduction in NAS without worsening fibrosis (demonstrated by both absence of ballooning [score=0] AND absence or mild lobular inflammation [score=0-1], plus no progression >= 1 fibrosis stage); OR (2) At least one stage improvement in fibrosis without worsening NAS; OR (3) Stabilization of fibrosis by blood tests (LFTs) and non-invasive assessments. Adherence to medication and lifestyle changes aiming for 7-10% weight loss is also required. Brand-specific criteria (3 generic equivalent failures) re-checked at renewal. Initial MASH fibrosis staging criteria (F2-F3, metabolic risk factors, alcohol limits) are NOT re-verified at continuation — only clinical response is assessed.

Not covered when

  • Stage 4 fibrosis (cirrhosis) — noncirrhotic MASH only
  • Other causes of steatotic liver disease (drug-induced, monogenic, alcohol-induced, cryptogenic)
  • Alcohol consumption >= 20 g/day for females or >= 30 g/day for males
  • Personal or family history of medullary thyroid carcinoma or MEN2
  • Prior serious hypersensitivity reaction to semaglutide
  • Concomitant use of GLP-1 receptor agonists or GIP/GLP-1 agonists
  • Chronic pancreatitis or recent (within 180 days) acute pancreatitis
  • Severe gastroparesis
  • Sustained increase in resting heart rate (continuation only)
  • Pregnancy

Policy note: This PCG applies to Commercial and/or Marketplace plans. It does NOT apply to Federal Employee Program, Medicare Advantage, Medicaid, or out-of-state BCBS plans. Metabolic risk factors (need 3 of 5): (1) large waist circumference (men > 94 cm / women > 80 cm) OR BMI >= 30 kg/m2; (2) TG >= 150 mg/dL or on specific treatment; (3) HDL < 40 mg/dL (males) or < 50 mg/dL (females) or on specific treatment; (4) BP >= 140/90 mmHg on two occasions or on treatment; (5) T2DM diagnosis. Liver biopsy lookback is 2 years (24 months), with no significant weight change > 5% and no medication that might affect NAS or fibrosis stage. FibroScan/VCTE lookback is 3 months. No explicit lookback period stated for biochemical tests (PRO-C3, ELF) or FIB-4 combination approach. The MASH indication is approved under FDA accelerated approval. Brand-specific criteria require failure, contraindication, or intolerance to THREE generic equivalents (if available) for at least 3 months each. Manufacturer samples/assistance not accepted for continuation of therapy. Initial approval is 6 months or end of plan year; continuation is 12 months or end of plan year. Diabetes (T2DM) is listed as a qualifying metabolic risk factor, so T2DM is NOT excluded for this indication.

Policy effective May 16, 2024 · verified June 2, 2026 · source: Download

Why Wegovy requests get denied by BCBS Arizona

Based on what this policy asks for. Fix these before the first submission.

  1. Your plan's benefit excludes weight loss medications. A prior authorization cannot override a benefit exclusion — ask about a formulary exception or a different covered pathway.
  2. Wrong brand for the diagnosis. Wegovy and Ozempic are the same molecule with different approved uses; a request for Wegovy under a diagnosis that matches Ozempic is routinely denied.
  3. BMI not documented in the chart notes (or documented without a baseline weight and date).
  4. No documented diet and exercise program.
  5. Prescriber isn't the specialist the plan requires.
  6. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

If weight loss isn't covered on your plan

BCBS Arizona has separate Wegovy policies that don't depend on the weight loss benefit:

Wegovy is also sold directly by Novo Nordisk without insurance through NovoCare.

Frequently asked questions

Does BCBS Arizona cover Wegovy?
BCBS Arizona does not cover it for weight loss on Employer / Commercial Insurance and ACA Marketplace.
How long does a Wegovy approval last with BCBS Arizona?
Initial approvals last 6 months, and renewals are granted in 12-month periods.
What does BCBS Arizona require to renew Wegovy?
At least 5% weight loss from the starting weight, At renewal, patient must have achieved and maintained ONE of: (1) >= 5% reduction in body weight from baseline, OR (2) >= 3% body weight reduction from baseline WITH at least one of: decrease in LDL or triglycerides, decrease in waist circumference, or decrease in blood pressure. Also requires continued adherence to medication and guideline-directed standard of care for established CV condition. Minimum dose of 1.7 mg weekly required at renewal. HbA1c < 6.5% and absence of T1DM/T2DM are re-verified at continuation. GDMT requirement is re-verified at continuation (adherence required). Note: brand-specific criteria (3 generic equivalent failures) are also re-checked at renewal, and staying on a maintenance dose of at least 1.7 mg.
What if my plan excludes weight loss medications?
BCBS Arizona has separate Wegovy policies for heart disease risk reduction and liver disease (mash), which are covered on some plan types and don't depend on the weight-loss benefit. Wegovy is also available for cash through NovoCare.
How current is this information?
This page reflects BCBS Arizona's written policy as of May 16, 2024, last verified against the source document on June 2, 2026.

Other medications under BCBS Arizona

Wegovy coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Arizona's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.